BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 205 filers reported holding BRIDGEBIO PHARMA INC in Q1 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,996,675 | +2365.0% | 830,193 | +2278.8% | 0.35% | +8625.0% |
| Q2 2022 | $81,000 | -17.3% | 34,900 | -45.6% | 0.00% | 0.0% |
| Q1 2022 | $98,000 | -99.1% | 64,100 | -95.4% | 0.00% | -98.6% |
| Q4 2021 | $10,564,000 | +119.9% | 1,404,272 | +485.8% | 0.29% | +84.1% |
| Q3 2021 | $4,805,000 | +35.6% | 239,732 | +21.5% | 0.16% | +42.7% |
| Q2 2021 | $3,543,000 | -10.3% | 197,279 | +3.8% | 0.11% | -48.1% |
| Q1 2021 | $3,949,000 | +1243.2% | 190,091 | +43.9% | 0.21% | +1225.0% |
| Q2 2020 | $294,000 | -18.1% | 132,100 | +31.7% | 0.02% | -33.3% |
| Q1 2020 | $359,000 | – | 100,300 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |